External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

被引：0
|
作者：
Paganelli, G. [1 ]
Rossetti, C. [2 ]
Aglietta, M. [3 ]
Messina, C. [4 ]
Versari, A. [5 ]
Michalski, J. M. [6 ]
O'Sullivan, J. M. [7 ]
Parker, C. [8 ,9 ]
Garcia-Vargas, J. E. [10 ]
Sartor, A. [11 ]
Finkelstein, S. E. [12 ]
机构：
[1] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, IT, Italy
[2] AO Osped Niguarda Ca Granda, Milan, Italy
[3] IRCCS Candiolo, Candiolo, TO, Italy
[4] AO Papa Giovanni XXIII, Bergamo, IT, Italy
[5] IRCCS AO Arcispedale S Maria Nuova, Reggio Emilia, IT, Italy
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Queens Univ, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[9] Inst Canc Res, Sutton, Surrey, England
[10] Bayer HealthCare, Whippany, NJ USA
[11] Tulane Canc Ctr, New Orleans, LA USA
[12] 21st Century Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F31
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [21] Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: Baseline prognostic factor subgroup analysis
    O'Sullivan, J.
    Johannessen, D. C.
    Widmark, A.
    Syndikus, I.
    James, N.
    Dall'Oglio, M.
    Haugen, I.
    Cross, A.
    Garcia-Vargas, J.
    Vogelzang, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
  • [22] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Hematologic safety of Ra-223 dichloride (Ra-223) in castration- resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Fang, F.
    Vogelzang, N. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 60
  • [24] Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option
    Causer, L.
    Johnson, B.
    Sicari, R.
    Lavent, F.
    Lien, L. M. E.
    Jensen, T.
    Wahba, M.
    Parker, C.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S21 - S21
  • [25] 1.5-YEAR POSTTREATMENT FOLLOW-UP OF RADIUM-223 DICHLORIDE (RA-223) SAFETY IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES FROM ALSYMPCA: CHARACTERIZATION OF HEMATOLOGIC SAFETY PROFILES
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R. E.
    Skjorestad, I.
    Aksnes, A.
    Wahba, M.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [26] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wedel, S.
    Wiechno, P.
    Helle, S., I
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 87
  • [27] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [28] Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases
    Stroelin, P.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    Tear, C. G. O'Bryan
    Staudacher, K.
    Vargas, J. E. Garcia
    Zou, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [29] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [30] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S. I.
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    Tear, C. G. O'Bryan
    Shan, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
12345